IN2014DN09990A - - Google Patents

Download PDF

Info

Publication number: IN2014DN09990A
Authority: IN; India
Prior art keywords: individual; pterostilbene; glucuronosyltransferase; ugt; udp
Prior art date: 2012-05-08

Application number

Other languages

English (en)

Inventor

Jeremy Bartos

Ryan Dellinger

Original Assignee

Chromadex Inc

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-08

Filing date

2012-11-14

Publication date

2015-08-14

2012-11-14 Application filed by Chromadex Inc, Univ California filed Critical Chromadex Inc

2015-08-14 Publication of IN2014DN09990A publication Critical patent/IN2014DN09990A/en

Links

102000016354 Glucuronosyltransferase Human genes 0.000 abstract 2
108010092364 Glucuronosyltransferase Proteins 0.000 abstract 2
VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 abstract 2
VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 abstract 2
ZNHVWPKMFKADKW-LQWMCKPYSA-N 12(S)-HETE Chemical compound CCCCC\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-LQWMCKPYSA-N 0.000 abstract 1
ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Physiology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Nutrition Science (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

IN9990DEN2014 2012-05-08 2012-11-14 IN2014DN09990A (2)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13/466,827 US8841350B2 (en)	2011-05-11	2012-05-08	Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
PCT/US2012/064993 WO2013169291A2 (en)	2012-05-08	2012-11-14	Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Publications (1)

Publication Number	Publication Date
IN2014DN09990A true IN2014DN09990A (2)	2015-08-14

Family

ID=47142275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN9990DEN2014 IN2014DN09990A (2)	2012-05-08	2012-11-14

Country Status (12)

Country	Link
US (2)	US8841350B2 (2)
EP (1)	EP2846785A4 (2)
JP (1)	JP2015523963A (2)
KR (1)	KR20150027081A (2)
CN (1)	CN104768543A (2)
AU (1)	AU2012379655B2 (2)
BR (1)	BR112014027646A2 (2)
CA (1)	CA2872623A1 (2)
IN (1)	IN2014DN09990A (2)
MX (1)	MX2014013503A (2)
WO (1)	WO2013169291A2 (2)
ZA (1)	ZA201408893B (2)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9980924B2 (en) *	2014-09-04	2018-05-29	The Regents Of The University Of California	Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin
WO2016037007A1 (en) *	2014-09-04	2016-03-10	The Regents Of The University Of California	Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
JP2018517774A (ja) *	2015-06-10	2018-07-05	エリジウム・ヘルス・インコーポレイテッド	ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
US12134956B2 (en)	2022-10-11	2024-11-05	Halliburton Energy Services, Inc.	Liner hanger system
US12398624B2 (en)	2023-07-11	2025-08-26	Halliburton Energy Services, Inc.	Self-energizing seal for expandable liner hanger
US12509957B1 (en)	2024-09-16	2025-12-30	Halliburton Energy Services, Inc.	Partially bonded seals for well systems

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6623724B2 (en) *	1996-09-18	2003-09-23	Applied Genetics Incorporated Dermatics	Dermatological compositions and methods
US6414037B1 (en) *	1998-01-09	2002-07-02	Pharmascience	Pharmaceutical formulations of resveratrol and methods of use thereof
DE10161253A1 (de)	2001-12-13	2003-06-26	Dragoco Gerberding Co Ag	Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren
FR2869229B1 (fr)	2004-04-26	2006-08-25	Sederma Soc Par Actions Simpli	Utilisation d'un inducteur des ugt par voie topique
ES2246165B1 (es)	2004-07-20	2006-12-01	Universitat De Valencia	Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
WO2008070872A1 (en)	2006-12-07	2008-06-12	Rutgers, The State University Of New Jersey	Prevention and treatment of colon cancer
US8509879B2 (en)	2007-11-06	2013-08-13	The Regents Of The University Of California	Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging
AU2009204177B9 (en) *	2008-01-08	2014-08-14	Reswine Llc	Method and compositions for preserving wine
US20090324740A1 (en)	2008-06-13	2009-12-31	Albritton Iv Ford D	Novel nasal spray
US20100240767A1 (en)	2009-03-23	2010-09-23	Muhammed Majeed	Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
ES2798254T3 (es)	2009-06-22	2020-12-10	Indus Biotech Private Ltd	Proceso para la obtención de pteroestilbeno purificado y métodos de uso del mismo
WO2011042482A1 (en) *	2009-10-06	2011-04-14	Green Molecular	Polyphenols for use in the treatment of cancer
EP2322159A1 (en)	2009-10-30	2011-05-18	Green Molecular, S.L.	Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US8318807B2 (en) *	2010-02-03	2012-11-27	Laurus Labs Private Limited	Pterostilbene cocrystals
US8883218B2 (en) *	2010-03-26	2014-11-11	The Board Of Trustees Of The University Of Arkansas	Anti-cancer nanoparticle compositions and methods of use
CN110015962B (zh)	2011-01-28	2022-03-15	肯塔基大学研究基金会	茋类似物和治疗癌症的方法
JP6155191B2 (ja) *	2011-10-02	2017-06-28	キユーピー株式会社	ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途

2012
- 2012-05-08 US US13/466,827 patent/US8841350B2/en active Active - Reinstated
- 2012-11-14 BR BR112014027646A patent/BR112014027646A2/pt not_active IP Right Cessation
- 2012-11-14 JP JP2015511433A patent/JP2015523963A/ja active Pending
- 2012-11-14 MX MX2014013503A patent/MX2014013503A/es unknown
- 2012-11-14 IN IN9990DEN2014 patent/IN2014DN09990A/en unknown
- 2012-11-14 CN CN201280074486.2A patent/CN104768543A/zh active Pending
- 2012-11-14 CA CA2872623A patent/CA2872623A1/en not_active Abandoned
- 2012-11-14 EP EP12876092.3A patent/EP2846785A4/en not_active Withdrawn
- 2012-11-14 WO PCT/US2012/064993 patent/WO2013169291A2/en not_active Ceased
- 2012-11-14 KR KR20147034337A patent/KR20150027081A/ko not_active Withdrawn
- 2012-11-14 AU AU2012379655A patent/AU2012379655B2/en not_active Expired - Fee Related
2014
- 2014-09-22 US US14/493,058 patent/US10039725B2/en active Active - Reinstated
- 2014-12-04 ZA ZA2014/08893A patent/ZA201408893B/en unknown

Also Published As

Publication number	Publication date
KR20150027081A (ko)	2015-03-11
EP2846785A4 (en)	2016-06-15
US8841350B2 (en)	2014-09-23
CN104768543A (zh)	2015-07-08
BR112014027646A2 (pt)	2017-06-27
JP2015523963A (ja)	2015-08-20
US10039725B2 (en)	2018-08-07
US20150011650A1 (en)	2015-01-08
US20120289605A1 (en)	2012-11-15
CA2872623A1 (en)	2013-11-14
WO2013169291A2 (en)	2013-11-14
AU2012379655A1 (en)	2014-11-20
ZA201408893B (en)	2016-08-31
AU2012379655B2 (en)	2018-01-18
MX2014013503A (es)	2015-11-13
WO2013169291A3 (en)	2015-06-18
EP2846785A2 (en)	2015-03-18

Publication	Publication Date	Title
PH12019501197A1 (en)	2020-08-24	Therapeutically active compounds and their methods of use
PH12016500164B1 (en)	2023-11-08	Therapeutically active compounds and their methods of use
PH12014501561A1 (en)	2014-10-08	Therapeutically active compounds and their methods of use
PH12014502048B1 (en)	2020-10-28	Treatment of cancer with tor kinase inhibitors
BR112015022197A2 (pt)	2017-07-18	tratamento de cataplexia
BR112012033738A2 (pt)	2017-08-08	método para o tratamento de transtorno bipolar
IN2014DN09990A (2)	2015-08-14
PH12014502046B1 (en)	2020-10-16	Treatment of cancer with tor kinase inhibitors
PH12018502731A1 (en)	2020-05-04	Treatment of cancer with dihydropyrazino-pyrazines
PH12013502144A1 (en)	2017-10-25	Multiple myeloma treatment
MX392388B (es)	2025-03-24	Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe)
MX2014002112A (es)	2014-09-25	Compuestos de pirimido-piridazinona y uso de los mismos.
MX2015013186A (es)	2016-04-15	Adminitracion craneal de productos farmaceuticos.
BR112012008310A2 (pt)	2017-06-06	métodos para tratamento de tumores cerebrais
GB2525517A (en)	2015-10-28	Topical preparation for pain relief
MX2014014814A (es)	2015-02-12	Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX368640B (es)	2019-10-09	Composición farmacéutica para tratar inflamación y dolor.
MX359171B (es)	2018-09-18	Tratamiento para diabetes tipo i y tipo ii.
PH12015501980A1 (en)	2017-10-18	Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
UA82641U (ru)	2013-08-12	Способ лечения нейросифилиса с паренхиматозными изменениями
UA58066U (ru)	2011-03-25	Способ лечения генитальной вирусной инфекции
UA46514U (ru)	2009-12-25	Способ местного лечения ограниченной склеродермии